|
63
|
231
|
4qwsE |
Ycp beta5-c63f mutant in complex with carfilzomib |
|
59
|
222
|
4qluL |
Ycp in complex with tripeptidic epoxyketone inhibitor 9 |
|
62
|
222
|
4r02L |
Ycp in complex with bsc4999 (alpha-keto phenylamide) |
|
64
|
241
|
4qw7G |
Ycp beta5-m45t mutant in complex with carfilzomib |
|
57
|
204
|
4qv6I |
Ycp beta5-a49v mutant |
|
71
|
211
|
4r17K |
Ligand-induced aziridine-formation at subunit beta5 of the yeast 20s proteasome |
|
57
|
204
|
4qw5I |
Ycp beta5-m45a mutant in complex with carfilzomib |
|
59
|
222
|
4qvwL |
Ycp beta5-a49s-mutant in complex with bortezomib |
|
61
|
195
|
4qv3J |
Ycp beta5-m45v mutant |
|
62
|
222
|
4r17L |
Ligand-induced aziridine-formation at subunit beta5 of the yeast 20s proteasome |
|
60
|
241
|
4qwkG |
Ycp beta5-a49t-a50v-double mutant in complex with carfilzomib |
|
58
|
226
|
4qv0H |
Ycp beta5-a49t-a50v-double mutant |
|
60
|
195
|
4r17J |
Ligand-induced aziridine-formation at subunit beta5 of the yeast 20s proteasome |
|
67
|
233
|
4qz3M |
Ycp beta5-a49v mutant in complex with the epoxyketone inhibitor onx 0914 |
|
64
|
240
|
4qwsC |
Ycp beta5-c63f mutant in complex with carfilzomib |
|
61
|
195
|
4qv7J |
Ycp beta5-a50v mutant |
|
57
|
222
|
4qzxH |
Ycp beta5-c63f mutant in complex with the epoxyketone inhibitor onx 0914 |
|
69
|
250
|
4qwgA |
Ycp beta5-a49v mutant in complex with carfilzomib |
|
69
|
240
|
4qwuC |
Ycp beta5-c52f mutant in complex with bortezomib |
|
59
|
196
|
4qw3N |
Ycp beta5-c63f mutant in complex with bortezomib |
|
69
|
240
|
4qzxC |
Ycp beta5-c63f mutant in complex with the epoxyketone inhibitor onx 0914 |
|
60
|
196
|
4qwuN |
Ycp beta5-c52f mutant in complex with bortezomib |
|
56
|
204
|
4qw7I |
Ycp beta5-m45t mutant in complex with carfilzomib |
|
61
|
222
|
4qz4L |
Ycp beta5-a49s mutant in complex with the epoxyketone inhibitor onx 0914 |
|
62
|
195
|
4qwjJ |
Ycp beta5-a49t-mutant in complex with carfilzomib |
|
61
|
195
|
4qv9J |
Ycp beta5-c63f mutant |
|
76
|
250
|
4r3oC |
Human constitutive 20s proteasome |
|
71
|
243
|
4qz2F |
Ycp beta5-m45i mutant in complex with the epoxyketone inhibitor onx 0914 |
|
64
|
241
|
4qvwG |
Ycp beta5-a49s-mutant in complex with bortezomib |
|
65
|
231
|
4qv0E |
Ycp beta5-a49t-a50v-double mutant |
|
67
|
242
|
4qz5D |
Ycp beta5-a49t-mutant in complex with onx 0914 |
|
57
|
222
|
4qwxH |
Ycp in complex with the epoxyketone inhibitor onx 0914 |
|
71
|
244
|
4qv5B |
Ycp beta5-m45i mutant |
|
69
|
244
|
4qbyB |
Ycp in complex with boc-ala-ala-ala-cho |
|
67
|
242
|
4r00D |
Ycp beta5-c52f mutant in complex with omuralide |
|
62
|
241
|
4qwuG |
Ycp beta5-c52f mutant in complex with bortezomib |
|
55
|
204
|
4qvpI |
Ycp beta5-m45t mutant in complex with bortezomib |
|
65
|
231
|
4qz1M |
Ycp beta5-m45t mutant in complex with the epoxyketone inhibitor onx 0914 |
|
65
|
241
|
4qwfG |
Ycp beta5-m45i mutant in complex with carfilzomib |
|
59
|
196
|
4r02N |
Ycp in complex with bsc4999 (alpha-keto phenylamide) |
|
51
|
204
|
4r3oJ |
Human constitutive 20s proteasome |
|
72
|
240
|
4qwjC |
Ycp beta5-a49t-mutant in complex with carfilzomib |
|
115
|
367
|
4rafA |
Crystal structure of pp2ca-d38a |
|
71
|
240
|
4qz6C |
Ycp beta5-a49t-a50v double mutant in complex with the epoxyketone inhibitor onx 0914 |
|
62
|
195
|
4qv6J |
Ycp beta5-a49v mutant |
|
59
|
196
|
4qzzN |
Ycp in complex with omuralide |
|
66
|
212
|
4qw1K |
Ycp beta5-a50v mutant in complex with bortezomib |
|
66
|
231
|
4qv9E |
Ycp beta5-c63f mutant |
|
58
|
204
|
4qlqI |
Ycp in complex with tripeptidic epoxyketone inhibitor 8 |
|
69
|
243
|
4qvyF |
Ycp beta5-a49t-mutant in complex with bortezomib |
